16
Participants
Start Date
May 2, 2019
Primary Completion Date
June 17, 2022
Study Completion Date
March 17, 2023
IMA202 Product
The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
IMADetect®
IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only.
University of Pittsburgh Medical Center, Pittsburgh
Universitätsklinikum Hamburg-Eppendorf, Hamburg
Universitätsklinikum Bonn - Medizinische Klinik III, Bonn
University of Texas MD Anderson Cancer Center, Houston
Universitätsklinikum Würzburg, Würzburg
Universitätsklinikum C.-G.-Carus Dresden, Dresden
Immatics US, Inc.
INDUSTRY